Skip to main content

Table 2 Baseline characteristics of followed and non-followed subjects in the TLGS cohort, Tehran Lipid and Glucose Study (1999–2014)

From: Application of survival tree analysis for exploration of potential interactions between predictors of incident chronic kidney disease: a 15-year follow-up study

Variables Total
n = 10,333
Followed
n = 8238
Non-followed
n = 2095
Difference (95% CI)
Age (years) 39.24 (13.64) 39.29 (13.25) 39.02 (15.07) 0.27 (− 0.38, 0.92)
Total length of stay in the city (years) 32.68 (13.47) 32.88 (13.08) 31.88 (14.90) 1.00 (0.30, 1.69)
BMI (kg/m2) 26.44 (4.77) 26.50 (4.67) 26.20 (5.14) 0.29 (0.04, 0.54)
Waist circumference (cm) 87.23 (12.38) 87.42 (12.28) 86.47 (12.75) 0.95 (0.33, 1.56)
Wrist circumference (cm) 16.69 (1.34) 16.71 (1.34) 16.64 (1.32) 0.07 (0.01, 0.13)
Hip circumference (cm) 100.18 (9.34) 100.28 (9.17) 99.78 (9.98) 0.50 (0.02, 0.98)
FPG (mmol/l) 5.29 (1.59) 5.27 (1.53) 5.38 (1.83) − 0.10 (− 0.19, − 0.01)
TG (mmol/l) 1.83 (1.33) 1.84 (1.34) 1.80 (1.33) 0.04 (− 0.02, 0.11)
TC (mmol/l) 5.16 (1.15) 5.17 (1.14) 5.11 (1.17) 0.05 (0.01, 0.11)
HDL-C (mmol/l) 1.07 (0.28) 1.07 (0.28) 1.07 (0.28) − 0.00 (− 0.01, 0.01)
eGFR (mL/min/1.73 m2) 75.70 (10.53) 75.59 (10.49) 76.15 (10.70) − 0.56 (− 1.07, − 0.04)
SBP (mmHg) 116.59 (17.40) 116.49 (17.05) 116.99 (18.74) − 0.50 (− 1.33, 0.34)
DBP (mmHg) 76.34 (10.65) 76.39 (10.60) 76.15 (10.81) 0.23 (− 0.27, 0.75)
Heart rate (beats/min) 79.28 (11.54) 79.25 (11.50) 79.40 (11.71) − 0.15 (− 0.71, 0.40)
Educationa
 Level 1 (illiterate) 2202 (21.3) 1754 (21.3) 448 (21.4) 0.0086 (− 0.0119, 0.0289)
 Level 2 (< 9 years) 6000 (58.1) 4831 (58.6) 1169 (55.8)
 Level 3 (9–12 years) 1520 (14.7) 1203 (14.6) 317 (15.1)
 Level 4 (> 12 years) 611 (5.9) 450 (5.5) 161 (7.7)
Marital status
 Single 1814 (17.6) 1337 (16.2) 477 (22.8) 0.0759 (0.0540, 0.0979)
 Married 8149 (78.9) 6625 (80.4) 1524 (72.7)
 Divorced/widowed 370 (3.6) 276 (3.4) 94 (4.5)
FH-CVD in female relatives 840 (8.1) 669 (8.1) 171 (8.2) − 0.0009 (− 0.0293, 0.0275)
FH-CVD in male relatives 843 (8.2) 657 (8.0) 186 (8.9) − 0.019 (− 0.048, 0.009)
FHD in first-degree relatives 2801 (27.1) 2255 (27.4) 546 (26.1) 0.0107 (− 0.0066, 0.0280)
PAL
 Inactiveb 6827 (70.5) 5458 (70.7) 1369 (69.9) − 0.0063 (− 0.0239, 0.0114)
Smoking
 Never 7684 (75.6) 6207 (76.5) 1477 (72.1) − 0.0001 (− 0.0305, 0.0304)
 Past 702 (6.9) 567 (7.0) 135 (6.6)
 Current 1776 (17.5) 1339 (16.5) 437 (21.3)
Use of blood lipid lowering drugs 231 (2.2) 177 (2.1) 54 (2.6) − 0.0317 (− 0.0869, 0.0234)
Use of blood glucose lowering drugs 320 (3.1) 234 (2.8) 86 (4.1) − 0.0681 (− 0.1173, − 0.0189)
Use of anti hypertensive drugs 434 (4.2) 335 (4.1) 99 (4.7) − 0.0265 (− 0.0667, 0.0138)
Use of aspirin 933 (9.0) 717 (8.7) 216 (10.3) − 0.0316 (− 0.0599, -0.0034)
Use of diuretics 120 (1.2) 93 (1.1) 27 (1.3) − 0.0225 (− 0.0976, 0.0526)
Prevalence CVD 324 (3.1) 219 (2.7) 105 (5.0) − 0.1253 (− 0.1768, -0.0737)
  1. Figures are either mean (SD) or n (%) for continuously and categorically distributed variables, respectively
  2. TLGS Tehran Lipid and Glucose Study, BMI body mass index, FPG fasting plasma glucose, TG triglyceride, TC total cholesterol, HDL-C HDL cholesterol, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, FH-CVD family history of premature cardiovascular disease, FHD family history of diabetes mellitus, PAL physical activity level, CVD cardiovascular disease
  3. aThe adjusted risk differences (95% CI) between followed and non-followed participants regarding categorical variables were estimated by logistic regression adjrr command in stata
  4. bDoing exercise or labor less than three times a week or performing activities achieving < 600 metabolic equivalent of task (MET)